CARLSBAD, Calif. , Oct. 23, 2024 /PRNewswire/ -- Tyra Biosciences, Inc.
(Nasdaq: TYRA ), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on October 25, 2024 at 8:00 am ET to share interim clinical results of TYRA-300 from the SURF301 Phase 1/2 study in metastatic urothelial cancer (mUC). These data will be presented in a late-breaking oral presentation at the 36 th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, being held October 23-25, 2024 , in Barcelona, Spain . Gary Steinberg, MD, Professor of Urology, Department of Urology, Rush University Medical Center , will be joining members of TYRA's management team on the call and will be available during Q&A.
Conference Call Information TYRA is hosting a conference call and webcast on October 25, 2024 , at 8am ET to review the interim clinical data demonstrated with TYRA-300 in mUC. Participants may access a live webcast of the call and the associated slide presentation on the "For Investors" page of the TYRA website at https://ir.tyra.
bio . To participate via telephone, please register in advance at this link . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant I.
